SEARCH

SEARCH BY CITATION

References

  • Cutrona, G., Ulivi, M., Fais, F., Roncelia, S. and Ferrarini, M., Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts. J. exp. Med., 181, 699711 (1995).
  • Gregory, C. D., Murray, R. J., Edwards, C. F. and Rickinson, A. B., Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J. exp. Med., 167, 18111824 (1988).
  • Gregory, C. D., Rowe, M. and Rickinson, A. B., Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J, gen. Virol., 71, 14811495 (1990).
  • Henderson, S., Rowe, M., Gregory, C., Croom-carter, D., Wang, F., Longnecker, R., Kieff, E. and Rickinson, A. B., Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65, 11071115 (1991).
  • Hoffman, G., Lazarovitis, S. and Hayward, S., Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen. Proc. nat. Acad. Sci. (Wash.), 77, 29792983 (1980).
  • Inghirami, G., Grignani, F., Sternas, L., Lombardi, L., Knowles, D. M. and Dalla-favera, R., Down-regulation of LFA-1 adhesion receptors by c-myc oncogene in human B lymphoblastoid cells. Science, 250, 682686 (1990).
  • Lenoir, G. M. and Bornkamm, G. W., Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: proposal for a new scenario. Adv. viral. Oncol., 7, 173206 (1988).
  • Levin, A. M., Lymphoma in acquired immunodeficiency syndrome. Semin. Oncol., 17, 104112, (1990).
  • Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-mullen, P. M., Klein, G., Kurilla, M. G. and Masucci, M. G., Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (Lond.), 375, 685688 (1995).
  • Lombardi, L., Newcomb, E. W. and Dalla-favera, R., Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lympho-blasts. Cell, 49, 161170 (1987).
  • Magrath, I., The patogenesis of Burkitt's lymphoma. Adv. Cancer Res., 55, 133270 (1990).
  • Masucci, M. G., Torsteindottir, S., Colombani, B. J., Brautbar, C., Klein, E. and Klein, G., Down-regulation of class I HLA antigens and of the Epotein-Barr virus (EBV)-encoded latent membrane protein (LMP) in Burkitt lymphoma lines. Proc. nat. Acad. Sci. (Wash.), 84, 45674571 (1987).
  • Matsumura, M., Fremont, D. H., Peterson, P. A. and Wilson, I. A., Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science, 257, 927934 (1992).
  • Miller, G., The switch between latency and replication of Epstein-Barr virus. J. infec. Disease, 161, 833844 (1990).
  • Rickinson, A. B., Murray, R. J., Brooks, J., Griffin, H., Moss, D. J. and Masucci, M. G., T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv., 13, 5380 (1992).
  • Rowe, M., Lear, A. L., Croom-carter, D., Davies, A. H. and Rickinson, A. B., Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J. Viroi, 66, 122131 (1992).
  • Rowe, M., Rowe, D. T., Gregory, C. D., Young, L. S., Farrel, P. J., Rupani, H. and Rickinson, A. B., Differences in B-cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBOJ., 6, 27432751 (1987).
  • Ulaeto, D., Wallace, L., Morgan, A., Morein, B. and Rickinson, A. B., In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340. Europ. J. Immunol., 18, 16891697 (1988).
  • Wallace, L. E., Wright, J., Ulaeto, D. O., Morgan, A. J. and Rickinson, A. B., Identification of two T cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones. J.Virol, 65, 38213828 (1991).
  • Wang, F., Gregory, C., Sample, C., Rowe, M., Liebowitz, D., Murray, R., Rickinson, A. and Kieff, E., Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3c are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol., 64, 23092318 (1990).
  • Yates, J., Warren, N., Reisman, D. and Sugden, B., A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. nat. Acad. Sci. (Wash.), 81, 38063810 (1984).